ArchiveTumor-infiltrating lymphocytes (TIL) has a high degree of heterogeneity. Adoptive cellular immunotherapy is one of the important treatments of immunotherapy. It is effective in many advanced solid tumors treatment with few adverse reactions through TIL reinfusing after expansion in vitro. TIL also has the the role of the effectiveness of anti-tumor therapy. This article reviewed the clinical research progress of TIL therapy in different types of cancer, the research progress of TIL as a predictor of tumor prognosis, and the problems faced by TIL therapy, in order to provide the evidence for follow-up research and the clinical use of TIL therapy.
Bispecific antibody is an artificial antibody prepared by cell fusion or recombinant DNA technology that can specifically bind two antigens or two different epitopes of the same antigen at the same time. Immune checkpoint inhibitors have revolutionized the treatment paradigm for advanced solid tumors. However, not all types of malignancies respond to these drugs, and the response rate and treatment effect of cancer patients still need to be improved. This article reviewed the current status and progress of clinical research on dual-antibody drugs targeting programmed death ligand 1.
Non-small cell lung cancer (NSCLC) has an insidious onset, and some of the diagnosed cases are already in advanced stage, and most of them adopt platinum-based two-drug palliative chemotherapy regimen, but the safety of chemotherapy regimen is low, and patients often stop/change the drug due to intolerance to the adverse effects. Compound Kushen injection has the function of clearing heat and dampness, cooling blood and detoxifying, expelling nodules to relieve pain. It is widely used in clinical adjuvant treatment of NSCLC, which can help radiotherapy and chemotherapy to combat tumor, regulate tumor markers levels and prolong patients' survival period, as well as alleviate adverse effects, relieve cancer pain, improve patients' immunity and quality of life. This article reviewed the research progress of compound Kushen injection in the adjuvant treatment of NSCLC, to provide some ideas and basis for its application and research in the treatment of NSCLC.
Glucose-dependent insulinotropic ploypeptide (GIP) and glucagon-like peptide (GLP)-1 are two main types of incretin. Both of them can increase glucose-dependent insulin secretion and play a hypoglycemic role. In recent years, the efficacy of GLP-1 receptor agonists for diabetes mellitus type 2 (T2DM) has been widely recognized, but the effect of GIP on T2DM is still unclear. When GIP is combined with GLP-1 in a single molecule double agonist, it can show a significant synergistic effect. This article summarized the role of GIP/GLP-1 dual receptor agonists in glycemic control in patients with T2DM and the new findings from preclinical and clinical studies to provide reference for clinical practice.
Glucagon-like peptide-1 receptor agonist (GLP-1RA) is a widely used drug for treatment of diabetes mellitus type 2 (T2DM). It is especially effective for patients with metabolic syndrome such as obesity and hyperlipemia. At present, most GLP-1RA administration methods in the world are subcutaneous injection. Oral semaglutide is the first approved oral GLP-1RA daily preparation, which is formulated with the absorption enhancer N-[8-(2-hydroxyphenylmethyl) amino] salcaprozate sodium (SNAC). Oral semaglutide overcome the problem of peptide drug absorption in acidic gastric fluid. When oral smeiglutide is used alone or in combination with other hypoglycemic agents, it can play a good role in controlling blood glucose, reducing body weight and systolic blood pressure, and is well tolerated, and its safety is consistent with that of GLP- 1RA injection. This article reviewed the recent research progress on oral GLP-1RA in the treatment of T2DM, in order to provide clinical reference for clinic.
To explore the effects of ecotropic viral integration site 1 (EVI1) overexpression on K562 cells, and the molecular mechanism of DNA methyltransferase inhibitor decitabine in the treatment of chronic myelogenous leukemia (CML) with high expression of EVI1.
Retrovirus vectors were used to transfect K562 cells, and the expression level of micro RNA (miR)-9, the methylation degree of miR-9 promoter sequence and the number of cell clones in empty vector group and EVI1 group were detected. K562 cells with high EVI1 expression were treated with decitabine and solvent to detect the expression level of miR-9, methylation degree of miR-9 promoter sequence, number of cell clones and cell cycle.
Compared with the empty vector group and EVI1 group, the relative expression level of miR-9 was significantly decreased [(0.002 1±0.000 3) vs (0.003 4±0.000 3), P<0.01], and the methylation degree of miR-9 promoter sequence was significantly increased, cell proliferation was enhanced [(232.67±6.81) vs (124.67±5.03), P<0.01]. Compared with the solvent group, the expression level of miR-9 in decitabine group was significantly increased [(0.002 3±0.000 3) vs (0.000 7±0.000 1), P<0.01], and the methylation degree of miR-9 promoter was significantly decreased [(44.67±6.57)% vs (90.22±4.29)%, P<0.01], the cell proliferation ability was decreased [(173.67±12.06) vs (219.33±10.26), P<0.01], and the proportion of G0/G1 cells was increased [(59.25±1.20)% vs (50.45±1.06)%, P<0.05].
EVI1 down-regulates the expression of miR- 9 by increasing the methylation degree of miR-9 promoter, which may be one of the mechanisms of EVI1 participates in CML. Decitabine can reverse the methylation degree of miR-9 caused by EVI1 overexpression, and inhibit the cloning and proliferation ability of tumor cells, providing a theoretical basis for its use in the treatment of CML with EVI1 overexpression.
To investigate the effect of silymarin on hepatocyte apoptosis in rats with obstructive jaundice and the regulatory mechanism of extracellular signal regulated kinase (ERK)/p38 mitogen activated protein kinase (MAPK) pathway.
Forty SD rats were randomly selected from 50 SD rats to establish obstructive jaundice rats model, and 10 rats were set as sham operation group. The rats successfully modeled were randomly divided into model group, low (50 mg/kg), medium (100 mg/kg), and high (200 mg/kg) silymarin dose groups, with 10 rats in each group. The liver function indexes were detected after 4 weeks of drug intragastric administration. The levels of interleukin (IL)-6 and tumor necrosis factor (TNF)-α were measured by enzyme-linked immunosorbent assay. Liver histopathological changes and hepatocyte apoptosis were observed. The expressions of caspase-3 and caspase-9 in liver tissue were detected by immunohistochemical method. Western blotting was used to detect ERK/p38MAPK pathway-related proteins in liver.
Compared with model group, the liver tissue lesions of rats in low, medium and high dose of silymarin groups were gradually reduced with increasing dose, and the hepatocyte apoptosis rate was decreased (P<0.05). Compared with model group, liver function indexes, IL-6, TNF-α, caspase-3, caspase-9 protein expression, ERK and p38MAPK phosphorylation levels in low, medium and high dose of silymarin groups were decreased (P<0.05).
Silymarin can reduce hepatocyte apoptosis and improve hepatic injury in rats with obstructive jaundice, and the mechanism may be related to the inhibition of ERK/p38MAPK pathway.
To investigate the effect of Wenxin granule on patients with paroxysmal atrial fibrillation (PAF) and transforming growth factor (TGF)-β/Smads signaling pathway.
A total of 112 patients with PAF treated in our hospital from January 2020 to January 2021 were retrospectively collected. The patients were divided into treatment group (n=52) and control group (n=60) according to the treatment methods. The patients in both groups were given conventional therapy, and the treatment group was given Wenxin granule orally on this basis. The curative effect and the change of TGF-β/Smads signaling pathway of the two groups were observed.
After treatment, compared with the control group, the number of episodes of atrial fibrillation in the treatment group decreased significantly [(1.35±0.32) times/week vs (1.76±0.40) times/week, P<0.001]. The duration of atrial fibrillation was significantly shortened [(0.57±0.21) h/wee vs (0.83±0.36) h/week, P<0.05]. The resting ventricular rate decreased significantly [(81.49±7.27) beats/min vs (85.84±6.21) beats/min, P=0.001]. The maximum time limit of P wave decreased significantly [(108.12±8.21) ms vs (114.48±9.02) ms, P<0.001]. The P-wave dispersion decreased significantly [(36.78±5.82) ms vs (39.84±5.58) ms, P=0.005]. There was no significant difference in serum TGF-β1, p-Smad2 and p-Smad3 between the two groups before treatment (P>0.05). After treatment, compared with the control group, TGF- β1, P-Smad2 and P-Smad3 in the treatment group decreased significantly (P<0.05).
Wenxin granule can improve the prognosis of PAF patients, possibly by inhibiting TGF-β/Smads signaling pathway.
To explore the effects of vinpocetine combined with modified electroconvulsive therapy (MECT) on psychiatric symptoms, cognitive function and adverse reactions in patients with schizophrenia.
A total of 60 patients with schizophrenia admitted to Wuhan Mental Health Center from January 2018 to December 2019 were enrolled and divided into experimental group and control group according to random number table method, with 30 cases in each group. The experimental group was treated with vinpocetine combined with MECT, while the control group was treated with MECT combined with placebo. The clinical curative effect and changes of cognitive function were compared between the two groups by double-factor repeated ANOVA.
After 14d of treatment and at 4 weeks after the end of treatment, positive and negative syndrome scales scores in both groups were significantly lower than those before treatment (P<0.05). After 14 d of treatment, scores of speech function, visual memory, reasoning and problem-solving ability and social cognition in the control group, and score of speech function in the experimental group in MATRICS consensus cognitive set were significantly lower than those before treatment (P<0.05). The scores of speech function [(43.466±8.253) points vs (38.907±5.957) points], reasoning and problem-solving ability [(39.025±11.212) points vs (31.262±7.126) points] in the experimental group were significantly higher than those in the control group (P<0.05). At 4 weeks after treatment, scores of processing speed, speech function, visual memory and social cognition in the control group were significantly lower than those before treatment (P<0.05), and which were significantly higher in the experimental group than those in the control group [(39.424±12.795) points vs (30.523±12.919) points, (46.160±7.565) points vs (40.757±8.243) points, (43.566±10.178) points vs (36.991±10.292) points, P<0.05]. There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).
Vinpocetine can relieve cognitive impairment induced by MECT in schizophrenia patients.
By briefly introducing the extended cost-effectiveness analysis (ECEA) method and two cases, illustrated the application process and situation, and provided a useful reference for the application of ECEA in China.
The literature research method was used to collect, identify and sort out the literature related to ECEA in recent years for research.
Through ECEA case studies, it was found that after implementation of most health interventions, the poor people received the most health gains and financial risk protection.
ECEA can make up for the shortcomings of existing pharmacoeconomic evaluation methods, improve the efficiency of health resource allocation, and promote the development of health undertakings in a more stable and equitable direction, which has broad application prospects in China.
To observe the clinical effect of Tianmai Xiaoke tablet combined with traditional Chinese medicine diet in the treatment of impaired glucose tolerance (IGT).
A total of 96 patients with IGT diagnosed in our hospital from June 2018 to June 2019 were randomly divided into treatment group and control group, with 48 cases in each group. The control group was treated with Tianmai Xiaoke tablet, and the treatment group was treated with traditional Chinese medicine diet on the basis of the control group. After 12 months of treatment, the total effective rate before and after treatment was compared between the two groups, and fasting blood glucose and insulin, 2 h postprandial blood glucose and insulin and glycosylated hemoglobin were observed. The homeostasis model evaluated the changes in insulin resistance index, islet β cell function index, endo-media thickness, carotid artery stiffness, strain elasticity coefficient, compliance, and secreted frizzle-related changes in the levels of protein (SFRP)-4, Apelin-13 and C1q/tumor necrosis factor-related protein (CTRP)-5.
The total effective rate of traditional Chinese medicine syndrome in the treatment group was 91.67%, which was significantly better than that in the control group (70.83%, χ2=5.539, P<0.05). The rate of outcome of IGT in the treatment group was significantly higher than that in the control group (P<0.01), and the incidence of diabetes was significantly lower than that in the control group (P<0.01). After treatment, the levels of fasting blood glucose, fasting insulin, 2 h postprandial blood glucose, 2 h insulin, glycohemoglobin, insulin resistance index, intima-media thickness, carotid artery stiffness, strain elasticity coefficient, SFRP-4 and CTRP-5 in both groups were significantly decreased than before treatment (P<0.01). The function index, compliance level of pancreatic β cells and Apelin-13 were significantly higher than before treatment (P<0.01), and the decrease or increase significantly in the treatment group compared with the control group (P<0.01).
Tianmai Xiaoke tablet combined with traditional Chinese medicine diet can reduce IGT blood glucose, improve insulin resistance, relieve internal carotid atherosclerosis and improve vascular elasticity.
Calcium ion is an important second messengers in a variety of body reactions, such as cell degranulation associated with pseudoallergy. The process of calcium ion change involves many receptors, signal pathways and calcium flow channels, but the research results are not enough. This article summarized the cell membrane receptors related to the development of pseudo-allergy, the signal pathways and calcium release channels that further affect the changes of calcium level, and explain the important role of calcium ion in the development of pseudo-allergy from various aspects. By understanding the role of calcium ions in the process of cell degranulation, to further clarify the mechanism and influencing factors of drug action, in order to provide effective indicators for drug safety evaluation, and facilitate early prediction and screening.
Glucagon-like peptide-1 receptor agonist (GLP-1RA) is an important hypoglycemic agent, which has various metabolic effects. It plays an important role in reducing body mass and treating complications of diabetes mellitus type 2 (T2DM). In terms of efficacy, GLP-1RA had a proportion of adverse responses, including baseline glycosylated hemoglobin, islet beta cell function, GLP-1RA drug dose, body mass index, ethnicity or predictable partial glycaemia response. In terms of tolerance, most GLP-1RA tolerance was negatively correlated with the course of treatment. The comprehensive management of T2DM requires patient-centered individualized treatment. This paper summarized the baseline characteristics related to glucose response and tolerance in the treatment of T2DM by GLP-1RA, and explored the appropriate population characteristics for GLP-1RA, in order to provide some reference for clinical medication.
Explore the working pattern of pharmaceutical security in tertiary general hospital during the period of corona virus disease 2019. Establish a ''four-in-one'' matrix of parent hospital, designated hospital, square cabin hospitals, and internet hospital. While ensuring the supply of basic medicines, explore the model of pharmaceutical care, realize the transformation of patient-centered pharmaceutical care, and ensure the medication safety of patients.